Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
These suits represent the next frontier: whether manufacturers of regulated cannabis products may be held liable for injuries ...
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...
Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead ...
Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead increase the risk of chronic liver damage and cancer as we age.
KAIST scientists have created a fast-acting, stable powder hemostat that stops bleeding in one second and could significantly improve survival in combat and emergency medicine. Severe blood loss ...
After a bout of feeling tired all the time I'd put it down various factors, but then a doctor diagnosed me with an unexpected ...
The funding, part of a new ARPA-H bioprinting initiative, aims to create transplant-ready organs—potentially within ...
Mirum Pharmaceuticals, Inc. , a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and ...
What started out as a medication for diabetes and weight loss is offering something quite unexpected for many women. Experts ...
After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback